Rani Therapeutics Holdings, Inc. (RANI)
| Market Cap | 117.09M +333.9% |
| Revenue (ttm) | 4.88M +306.4% |
| Net Income | -30.14M |
| EPS | -0.22 |
| Shares Out | 139.40M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 371,088 |
| Open | 0.8600 |
| Previous Close | 0.8542 |
| Day's Range | 0.8360 - 0.8610 |
| 52-Week Range | 0.4404 - 3.8700 |
| Beta | 0.70 |
| Analysts | Strong Buy |
| Price Target | 7.20 (+757.14%) |
| Earnings Date | Aug 13, 2026 |
About RANI
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in prec... [Read more]
Financial Performance
In 2025, RANI's revenue was $1.63 million, an increase of 58.85% compared to the previous year's $1.03 million. Losses were -$29.67 million, -1.15% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for RANI stock is "Strong Buy." The 12-month stock price target is $7.2, which is an increase of 757.14% from the latest price.
News
Rani Therapeutics initiated with a Buy at Chardan
Chardan initiated coverage of Rani Therapeutics (RANI) with a Buy rating and $6 price target The company offers is “best-in-class” among oral delivery platforms for injectable biologics, the analyst t...
Rani Therapeutics reports Q2 EPS (4c), consensus (5c)
“We made significant progress in the second quarter, as we continue to expand the RaniPill oral delivery platform,” said Talat Imran, Chief Executive Officer of Rani Therapeutics (RANI). “We reported…
Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update
~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026 ~ ~ Announced positive initial Phase 1a data for RT-...
Rani Therapeutics Holdings Earnings release: Q2 2026
Rani Therapeutics Holdings released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Rani Therapeutics Holdings Quarterly report: Q2 2026
Rani Therapeutics Holdings has published its Q2 2026 quarterly earnings report on August 13, 2026.
Rani Therapeutics Holdings Transcript: Canaccord Genuity's 46th Annual Growth Conference
A novel oral biologics platform demonstrated strong phase I-A results for RT-114, with over 150% bioavailability and no new safety concerns. Strategic partnerships, including a $1B Chugai deal and collaborations with ProGen and PegBio, support a robust pipeline in obesity and immunology.
Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
SAN JOSE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced tha...
Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN JOSE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on ...
Rani Therapeutics reports initial data from RT-114 study
Rani Therapeutics (RANI) reported initial data from the ongoing Phase 1 study of RT-114, an orally administered RaniPill Capsule delivering PG-102, a GLP-1/GLP-2 dual agonist being developed by ProGen...
Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing
RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102 No adverse events attributed to RaniPill Capsule; treatment-related adverse events were mild ...
Rani Therapeutics announces research, development collaboration with PegBio
Rani Therapeutics (RANI) announced a research and development collaboration with PegBio to explore the delivery of multiple novel candidates from PegBio’s obesity and metabolic disease pipeline using ...
Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates
~ Collaboration will leverage the RaniPill® platform to explore oral delivery of PegBio's proprietary portfolio of novel obesity and metabolic disease molecules ~
Rani Therapeutics appoints Nicholas Maestas as CFO
Rani Therapeutics (RANI) announced the appointment of Nicholas Maestas as CFO, effective immediately. He succeeds Svai Sanford, who announced his departure in May to pursue another professional opport...
Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer
SAN JOSE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on ...
Rani Therapeutics Holdings Transcript: AGM 2026
The meeting confirmed quorum, elected seven directors, and ratified the auditor. Major highlights included a $1.085 billion Chugai partnership, significant financing rounds, and progress in clinical programs RT-114 and RT-116, positioning the company for future growth.
Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules
SAN JOSE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral deliver...
Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition
- Continued advancement of the ongoing Phase 1 study of RT-114 via RaniPill® for the treatment of obesity in collaboration with ProGen –
Rani Therapeutics Holdings Quarterly report: Q1 2026
Rani Therapeutics Holdings has published its Q1 2026 quarterly earnings report on May 15, 2026.
Rani Therapeutics Holdings Earnings release: Q1 2026
Rani Therapeutics Holdings released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference
SAN JOSE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral deliver...
Rani Therapeutics Holdings Proxy statement: Proxy filing
Rani Therapeutics Holdings filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Rani Therapeutics Holdings Proxy statement: Proxy filing
Rani Therapeutics Holdings filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy
SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral deliv...
Rani Therapeutics price target lowered to $5 from $9 at Canaccord
Canaccord lowered the firm’s price target on Rani Therapeutics (RANI) to $5 from $9 and keeps a Buy rating on the shares. The firm updated its model after the company…
Rani Therapeutics Holdings Earnings Call Transcript: Q4 2025
Significant progress was made in 2025, including a major Chugai partnership, strong pipeline advances, and improved financials with a cash runway into Q4 2027. RT-114 entered phase I trials, and the company is now debt-free.